2. Academic Validation
  3. PCLAF induces bone marrow adipocyte senescence and contributes to skeletal aging

PCLAF induces bone marrow adipocyte senescence and contributes to skeletal aging

  • Bone Res. 2024 Jul 4;12(1):38. doi: 10.1038/s41413-024-00337-5.
Lingqi Xie # 1,  Yalun Cheng # 1,  Biao Hu 1,  Xin Chen 1,  Yuze An 1,  Zhuying Xia 1,  Guangping Cai 1,  Changjun Li 1 2 3,  Hui Peng 4
Affiliations

Affiliations

  • 1 Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, Hunan, 410008, China.
  • 2 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, Hunan, 410008, China.
  • 3 Key Laboratory of Organ Injury, Aging and Regenerative Medicine of Hunan Province, Changsha, Hunan, 410008, China.
  • 4 Department of Endocrinology, Endocrinology Research Center, Xiangya Hospital of Central South University, Changsha, Hunan, 410008, China. penghui11083@csu.edu.cn.
  • # Contributed equally.
PMID: 38961077 DOI: 10.1038/s41413-024-00337-5
Abstract

Bone marrow adipocytes (BMAds) affect bone homeostasis, but the mechanism remains unclear. Here, we showed that exercise inhibited PCNA clamp-associated factor (PCLAF) secretion from the bone marrow macrophages to inhibit BMAds senescence and thus alleviated skeletal aging. The genetic deletion of PCLAF in macrophages inhibited BMAds senescence and delayed skeletal aging. In contrast, the transplantation of PCLAF-mediated senescent BMAds into the bone marrow of healthy mice suppressed bone turnover. Mechanistically, PCLAF bound to the ADGRL2 receptor to inhibit Akt/mTOR signaling that triggered BMAds senescence and subsequently spread senescence among osteogenic and osteoclastic cells. Of note, we developed a PCLAF-neutralizing antibody and showed its therapeutic effects on skeletal health in old mice. Together, these findings identify PCLAF as an inducer of BMAds senescence and provide a promising way to treat age-related osteoporosis.

Figures
Products